Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Jazz Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Jazz Pharmaceuticals' CEO'su Bruce Cozadd, Jan2003 tarihinde atandı, in görev süresi 21.75 yıldır. in toplam yıllık tazminatı $ 15.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.51% ine doğrudan sahiptir ve bu hisseler $ 35.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 11.4 yıldır.
Anahtar bilgiler
Bruce Cozadd
İcra Kurulu Başkanı
US$15.3m
Toplam tazminat
| CEO maaş yüzdesi | 7.8% |
| CEO görev süresi | 21.8yrs |
| CEO sahipliği | 0.5% |
| Yönetim ortalama görev süresi | 5.1yrs |
| Yönetim Kurulu ortalama görev süresi | 11.4yrs |
Son yönetim güncellemeleri
Recent updates
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$15m | US$1m | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$17m | US$1m | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$16m | US$1m | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$13m | US$1m | US$239m |
| Sep 30 2020 | n/a | n/a | US$179m |
| Jun 30 2020 | n/a | n/a | US$133m |
| Mar 31 2020 | n/a | n/a | US$280m |
| Dec 31 2019 | US$15m | US$1m | US$523m |
| Sep 30 2019 | n/a | n/a | US$609m |
| Jun 30 2019 | n/a | n/a | US$656m |
| Mar 31 2019 | n/a | n/a | US$486m |
| Dec 31 2018 | US$11m | US$979k | US$447m |
| Sep 30 2018 | n/a | n/a | US$520m |
| Jun 30 2018 | n/a | n/a | US$434m |
| Mar 31 2018 | n/a | n/a | US$447m |
| Dec 31 2017 | US$10m | US$950k | US$488m |
Tazminat ve Piyasa: Bruce 'nin toplam tazminatı ($USD 15.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 8.11M ).
Tazminat ve Kazançlar: Bruce 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Bruce Cozadd (60 yo)
21.8yrs
Görev süresi
US$15,341,235
Tazminat
Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 21.8yrs | US$15.34m | 0.51% $ 34.7m | |
| President & COO | less than a year | US$5.43m | 0.027% $ 1.8m | |
| Senior VP & Chief Accounting Officer | 5.2yrs | US$1.40m | Veri yok | |
| Executive VP & Chief Legal Officer | 5.3yrs | US$3.88m | 0.018% $ 1.2m | |
| Executive VP | 5.4yrs | US$4.98m | 0.046% $ 3.1m | |
| Executive VP & CFO | less than a year | Veri yok | 0.019% $ 1.3m | |
| VP & Head of Investor Relations | no data | Veri yok | Veri yok | |
| Executive VP & Chief People Officer | 5.9yrs | Veri yok | Veri yok | |
| Senior Vice President of Sleep & CNS Medicine | no data | Veri yok | Veri yok | |
| Executive VP & Chief Commercial OfficerChief Commercial Officer | 4.6yrs | Veri yok | 0.010% $ 702.5k | |
| Senior Vice President of Corporate Strategy | 5.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Technical Operations | 1.2yrs | Veri yok | 0.0021% $ 140.2k |
5.1yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: JAZZ 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 21.8yrs | US$15.34m | 0.51% $ 34.7m | |
| Independent Director | 20.8yrs | US$513.77k | 0.045% $ 3.0m | |
| Independent Director | 12.8yrs | US$531.27k | 1.89% $ 128.3m | |
| Independent Director | 11.4yrs | US$533.77k | 0.020% $ 1.3m | |
| Independent Director | 15.3yrs | US$526.27k | 0.034% $ 2.3m | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Lead Independent Director | 14.4yrs | US$571.27k | 0.015% $ 983.0k | |
| Independent Non-Executive Director | 3.8yrs | US$533.77k | 0.0088% $ 592.8k | |
| Independent Director | less than a year | Veri yok | 0.0024% $ 164.6k | |
| Independent Director | 11.4yrs | US$543.77k | 0.025% $ 1.7m | |
| Independent Non-Executive Director | 3.8yrs | US$521.27k | 0.0088% $ 592.8k | |
| Independent Director | 5.7yrs | US$523.77k | 0.018% $ 1.2m |
11.4yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: JAZZ 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.4 yıldır).